TMCnet News
Global Glaucoma Pipeline Therapeutics Report 2016: Pipeline Review of 59 Companies & 102 Drug Molecules - Research and MarketsResearch and Markets has announced the addition of the "Glaucoma - Pipeline Review, H2 2016" report to their offering. Glaucoma pipeline therapeutics constitutes close to 116 molecules, out of which approximately 102 molecules are developed by Companies and the remaining by the Universities/Institutes. Our latest report Glaucoma - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, or family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. The molecules developed by Companies in Pre-Registration, Filing Rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 9, 23, 9, 45, 11 and 1, respectively. Similarly, the Universities portfolioin Preclinical, Discovery and Unknown stages comprises 7, 6 and 1 molecules, respectively. Furthermore, this report also reviews key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/73l3m5/glaucoma.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006331/en/ |
